Category: EGFR + (Epidermal Growth Factor Receptor) Lung Cancer

Breakthrough Medicines Usher in Hopeful Era for Lung Cancer Patients

The Bonnie J. Addario Lung Cancer Foundation (ALCF) applauds the medical research community and the U.S. Food and Drug Administration (FDA) for putting a heightened focus on lung cancer diagnostics and treatments. ALCF works everyday to educate patients and their families on the latest advancements, encourage participation in clinical trials and fund life-saving research on… Read More

Posted by Dr. Guneet Walia on December 18th, 2015

FDA approves Necitumumab for Squamous NSCLC

The US FDA today approved Necitumumab or Portrazza in combination with two forms of chemotherapy – gemcitabine (Gemzar) and cisplatin (Platinol)- for the treatment of advanced, metastatic squamous non-small cell lung cancer (NSCLC) patients who have not been previously treated for their advanced lung cancer. Mechanism of Action: Necitumumab or Portrazza is a human monoclonal… Read More

Posted by Dr. Guneet Walia on November 24th, 2015

New treatment approved for drug-resistant lung cancer

Tagrisso approved for EGFR T790M mutation positive NSCLC patients In another win for lung cancer patients, the Food and Drug Administration today granted accelerated approval to Tagrisso (Osimertinib or AZD9291 manufactured by AstraZeneca) this morning for patients whose disease has progressed on EGFR-targeted therapies, and whose tumors express a specific mutation in EGFR- the T790M… Read More

Posted by Dr. Guneet Walia on November 13th, 2015

Expanded FDA Drug Approval Increases Lung Cancer Survivability, Hope for a Cure

Nivolumab now approved for both squamous and non-squamous NSCLC patients Diagnostic test to detect PDL1 expression also granted approval October 9, 2015. The most common type of lung cancer, non-small cell lung cancer (NSCLC) is divided into two subtypes- squamous cell and non-squamous cell lung cancer- depending on the specific kinds of cells found in the… Read More

Posted by Dr. Guneet Walia on October 9th, 2015

Got Young Lungs?

In July, 2014 we launched an international study to understand why young people under the age of 40 were increasingly being diagnosed with lung cancer- the Genomics of Young Lung study, the FIRST ever study to prospectively characterize the clinical characteristics and genomic alterations of young lung cancer. Our early data shows that 75% of all patients under 40 have… Read More

Posted by Dr. Guneet Walia on October 5th, 2015

Combination Therapy Better as Front-line Treatment for EGFR T790M+ NSCLC Patients

Approximately 15% of all non-small cell lung cancer (NSCLC) patients harbor mutations in the Epidermal Growth Factor Receptor (EGFR) gene. There are therapies that target these genomic aberrations and have proven clinical benefit in these patients, such as erlotinib, afatinib, and gefitinib. Data presented at the ASCO Annual Meeting last year demonstrated that the addition… Read More

Posted by Dr. Guneet Walia on October 3rd, 2015

MET Its Match? Targeted Therapy for Mutations in the MET Gene

We are progressively moving from treating lung cancer as one disease, to an era of lung cancer being a collection of separate subtypes, each driven by an oncogenic mutation that contributes to cancer initiation, progression and metastasis. We are now filling out the lung cancer pie-chart for these individual subtypes, and beginning to understand each… Read More

Posted by Dr. Guneet Walia on October 3rd, 2015

FDA Approves Keytruda/ Pembrolizumab for Non-Small Cell Lung Cancer

The US Food and Drug Administration (FDA) today granted accelerated approval to an immunotherapy drug, Keytruda or Pembrolizumab, for patients with advanced, metastatic non-small cell lung cancer (NSCLC) whose disease has progressed after other treatments (chemotherapy or targeted therapy) and whose tumors express the protein PDL1. Based on the FDA approval, patients with EGFR or… Read More

Posted by Dr. Guneet Walia on October 2nd, 2015

Hope on the Horizon: Advances in Lung Cancer Treatment and Survivorship Issues Presented at ASCO 2015

The 51st American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago during May 29- June 2, 2015 brought together 30,000 oncology professionals from around the world. Latest ground-breaking research was presented at the conference by world-renowned faculty and key opinion leaders discussing state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field. Many… Read More

Posted by Dr. Guneet Walia on August 4th, 2015

Established Class of Drugs, Bisphosphonates, Can Prevent and Treat Lung Cancer

Two studies by the researchers at the Icahn School of Medicine at Mount Sinai, published in the journal Proceedings of the National Academy of Sciences show that drugs commonly used to treat osteoporosis and skeletal metastases can be used to block the development and progression of a variety of cancers, including non-small cell lung cancer… Read More

Posted by Dr. Guneet Walia on December 1st, 2014